SEC Comment Letter for Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166) (BGMS) — Jun 12, 2019
Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166)
Date: June 12, 2019 · CIK: 0001130166 · Accession: 0000000000-19-009794
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-231923
Letter
June 12, 2019 Paul McBarron Chief Operating Officer & Chief Financial Officer Cyclacel Pharmaceuticals, Inc. 200 Connell Drive, Suite 1500 Berkeley Heights, NJ 07922 Re:Cyclacel Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed June 3, 2019 File No. 333-231923 Dear Mr. McBarron: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dorrie Yale at 202-551-8776 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Cliff M. Silverman
Show Raw Text
June 12, 2019
Paul McBarron
Chief Operating Officer & Chief Financial Officer
Cyclacel Pharmaceuticals, Inc.
200 Connell Drive, Suite 1500
Berkeley Heights, NJ 07922
Re:Cyclacel Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed June 3, 2019
File No. 333-231923
Dear Mr. McBarron:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dorrie Yale at 202-551-8776 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Cliff M. Silverman